Author(s): Rybakowski JK, Skibinska M, Suwalska A, LeszczynskaRodziewicz A, Kaczmarek L,
Abstract Share this page
Abstract OBJECTIVE: Matrix metalloproteinase 9 (MMP-9) has been implicated in a number of pathological conditions including cancer and heart diseases, and recently also in such neuropsychiatric disorders as schizophrenia and bipolar illness. Therefore, we investigated a possible association between functional polymorphisms of the MMP-9 gene and the response to lithium, the main mood-stabilizing drug in bipolar illness. METHODS: One hundred and nine bipolar patients treated with lithium for at least 5 years were analyzed. The lithium response was assessed as--excellent: no affective episodes during lithium treatment; partial: 50\% or more reduction in the episode index; no response: less than 50\% reduction, no change or worsening in the episode index. The -1562C/T MMP-9 gene polymorphism (rs3918242) was assessed by PCR-RFLP method. RESULTS: Genotype distributions were not in Hardy-Weinberg equilibrium. No association was found between polymorphism studied and the quality of response to prophylactic lithium administration. CONCLUSION: The functional polymorphism of the MMP-9 gene, analyzed in this study, may not be associated with the treatment response to lithium in bipolar patients. Copyright © 2011 John Wiley & Sons, Ltd.
This article was published in Hum Psychopharmacol
and referenced in Journal of Pharmacogenomics & Pharmacoproteomics